Seborrhoeic Dermatitis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Arcutis Biotherapeutics, Cutanea Life Sciences, DermBiont, Astion Pharma

Posted on
by

Seborrhoeic Dermatitis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Arcutis Biotherapeutics, Cutanea Life Sciences, DermBiont, Astion Pharma
Seborrhoeic Dermatitis Pipeline Analysis
DelveInsight’s, “Seborrhoeic Dermatitis – Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Seborrhoeic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

According to DelveInsight, more than five key companies are actively engaged in developing over five treatment therapies for Seborrhoeic Dermatitis, highlighting ongoing efforts in this area.

Seborrhoeic Dermatitis Overview:

Seborrheic dermatitis is a long-term inflammatory skin disorder that mainly affects areas rich in sebaceous glands, such as the scalp, face, chest, back, armpits, and groin. It is estimated to impact about 4% of the population. Although the exact cause is not fully known, the condition is thought to be triggered by either an overgrowth of Malassezia—a normally harmless yeast present on the skin—or an exaggerated immune response to it. Diagnosis is usually made based on the rash’s location and appearance, with skin biopsies rarely required. Treatment aims to lower yeast levels on the skin, commonly using medicated creams and shampoos that are generally safe for long-term use.

Request for a detailed insights report on Seborrhoeic Dermatitis pipeline insights @ https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

“Seborrhoeic Dermatitis Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Seborrhoeic Dermatitis Therapeutics Market.

Key Takeaways from the Seborrhoeic Dermatitis Pipeline Report

  • DelveInsight’s Seborrhoeic Dermatitis pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Seborrhoeic Dermatitis treatment.

  • Key Seborrhoeic Dermatitis companies such as Arcutis Biotherapeutics, Cutanea Life Sciences, DermBiont, Astion Pharma A/S, Amorepacific, and others are evaluating new drugs for Seborrhoeic Dermatitis to improve the treatment landscape.

  • Promising Seborrhoeic Dermatitis pipeline therapies in various stages of development include Topical roflumilast foam (ARQ-154), Omiganan (CLS002), DBI-002, PAC-14028, and others.

  • Recent research has shown that seborrheic dermatitis has a unique immune profile, setting it apart from other skin conditions such as atopic dermatitis and plaque psoriasis. Additionally, disruptions in the skin barrier have been associated with alterations in specific gene expression patterns.

  • DermBiont has completed patient enrollment for a Phase 2b clinical trial evaluating SM-020 gel 1.0% for seborrheic keratoses, with topline results anticipated in the third quarter of 2024. If the outcomes are positive, the company may engage with the FDA to discuss the design of a potential Phase 3 trial.

  • The FDA has also approved roflumilast foam 0.3% (Zoryve) for the treatment of seborrheic dermatitis in patients aged 9 and older. This steroid-free, once-daily foam introduces a new treatment option for managing the condition.

Seborrhoeic Dermatitis Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights into the key companies that are developing therapies in the Seborrhoeic Dermatitis Market.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Seborrhoeic Dermatitis treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Seborrhoeic Dermatitis market.

Download our free sample page report on Seborrhoeic Dermatitis pipeline insights

Seborrhoeic Dermatitis Emerging Drugs

  • Topical roflumilast foam (ARQ-154): Arcutis Biotherapeutics

  • Omiganan (CLS002): Cutanea Life Sciences

  • DBI-002: DermBiont

  • PAC-14028: Amorepacific

Seborrhoeic Dermatitis Companies

More than five key companies are actively involved in developing treatments for seborrheic dermatitis. Among them, Arcutis Biotherapeutics and others have drug candidates currently in mid to advanced stages of development, particularly in Phase II clinical trials.

DelveInsight’s report covers around 5+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Seborrhoeic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Seborrhoeic Dermatitis Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Seborrhoeic Dermatitis Therapies and Key Companies: Seborrhoeic Dermatitis Clinical Trials and advancements

Seborrhoeic Dermatitis Pipeline Therapeutic Assessment

• Seborrhoeic Dermatitis Assessment by Product Type

• Seborrhoeic Dermatitis By Stage

• Seborrhoeic Dermatitis Assessment by Route of Administration

• Seborrhoeic Dermatitis Assessment by Molecule Type

Download Seborrhoeic Dermatitis Sample report to know in detail about the Seborrhoeic Dermatitis treatment market @ Seborrhoeic Dermatitis Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Seborrhoeic Dermatitis Current Treatment Patterns

4. Seborrhoeic Dermatitis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Seborrhoeic Dermatitis Late-Stage Products (Phase-III)

7. Seborrhoeic Dermatitis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Seborrhoeic Dermatitis Discontinued Products

13. Seborrhoeic Dermatitis Product Profiles

14. Seborrhoeic Dermatitis Key Companies

15. Seborrhoeic Dermatitis Key Products

16. Dormant and Discontinued Products

17. Seborrhoeic Dermatitis Unmet Needs

18. Seborrhoeic Dermatitis Future Perspectives

19. Seborrhoeic Dermatitis Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Seborrhoeic Dermatitis Pipeline Reports Offerings

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/